Skip to content

In patients having restriction in shoulder joint movement and pain due to soft tissue lesions, ultrasound guided highly concentrated dextrose solutions with property of healing, will be injected in the soft tissues, for improvement in movement with reduction in associated chronic pain.

Effect of Ultrasound-guided Hypertonic Dextrose Prolotherapy on Functional Outcomes in Patients with Rotator Cuff Pathology - nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/102805
Enrollment
40
Registered
2026-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M678- Other specified disorders of synovium and tendon

Interventions

Intervention1: hgftyfgjhfutiu: jftuyhjfyyug Intervention2: Ultrasound-guided Hypertonic Dextrose Prolotherapy: In this study, we will do your screening and a pre-intervention checkup will be done. Pat

Sponsors

Government Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with chronic shoulder pain of more than 3 months of duration, with Rotator cuff pathology as confirmed by definitive clinical diagnosis ( history and physical examination, including special test- Neer, Hawkins-Kennedy and drop arm test.) 2. Magnetic resonance imaging (MRI) confirming the evidence of RC pathology (partial thickness tear, tendinosis and/or bursitis ) and having strong correlation with physical examination findings. 3. Age range between 18 and 70 years.

Exclusion criteria

Exclusion criteria: 1. Previous shoulder surgery. 2. Full thickness rotator cuff lesions on MRI scan. 3. Shoulder fracture within past 6 months. 4. Patient having calcific tendinitis, adhesive capsulitis or glenohumeral osteoarthritis. 5. Patient with inflammatory and systemic rheumatic disorders. 6. Pregnant and lactating women. 7. Severe bleeding diathesis or on anticoagulation therapy. 8. Patient with severe systemic illness ( heart, lung, hepatic, renal , psychiatric , connective tissue disorder, neurological, uncontrolled diabetes mellitus or hypertension.) 9. Presence of systemic infection or local infection at the injection site. 10. Significant allergic reaction or hypersensitivity to corticosteroid, local anaesthetic, or dextrose. 11. Patient diagnosed with malignancy. 12. Unwillingness to abstain from NSAIDS for at least 3 days post-intervention 13. Patient taken any mode of corticosteroid therapy (systemic, injection) in past 2 months. 14. Presence of joint prosthesis or joint instability.

Design outcomes

Primary

MeasureTime frame
Shoulder Pain and Disability Index (SPADI) scoreTimepoint: Baseline Shoulder Pain and Disability Index (SPADI) score and 1, 2, and 3 months after third prolotherapy session

Secondary

MeasureTime frame
Active range of motion ( abduction, forward flexion, internal rotation, external rotation of shoulder measured by goniometer( angle at onset of pain will be measured three times to obtain median value)Timepoint: Baseline Active range of motion and at 1, 2, and 3 months after third prolotherapy session;Overall shoulder satisfaction measured by Likert scaleTimepoint: At 1, 2, and 3 months after third prolotherapy session;Average shoulder pain at movement in preceding 1 week measured by visual analogue scale ( VAS- week)Timepoint: Baseline VAS- week and at 1, 2, and 3 months after third prolotherapy session;Muscle strength testing measured by medical research council scale (MRC)Timepoint: Baseline muscle strength and at 3 months after third prolotherapy session;Any adverse eventsTimepoint: Recorded peri ntervention and post intervention

Countries

India

Contacts

Public ContactDr Riya Aggarwal

Government Medical College and Hospital, Chandigarh

kapoor.dheeraj72@gmail.com9646121549

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026